ERT Announces Availability of Wireless ECG /eCOA Tablet Integration
PHILADELPHIA (PRWEB) June 04, 2015 -- ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, today announced the availability of a new solution to wirelessly integrate ECG data collection with an electronic Clinical Outcome Assessments (eCOA) tablet – reducing site burden while improving data quality in clinical research. With the wireless ECG / eCOA tablet solution, a small, lightweight, wireless ECG device is unified with a tablet, which streamlines data collection, eases burden on investigative site staff and improves data quality with real-time data capture. Leveraging the integrated solution, clinical researchers collect vital, objective cardiac safety endpoint data along with patient and clinician reported outcome data, resulting in a more comprehensive view into patient health and well-being.
ERT’s wireless ECG / eCOA tablet solution is shipped to investigative sites preconfigured for data collection and ready for immediate use. During site visits, patient ECG and eCOA data are collected and automatically transmitted to the ERT Insights Cloud™, a private clinical research system accessible to qualified study personnel in real-time online. This robust, secure and validated clinical research workflow simplifies electronic data collection, data management and information exchange, dramatically reducing both site workload and the volume of queries generated.
“Cardiac safety continues to be the primary reason for drug withdrawals,” explained Amy Furlong, Executive Vice President, Cardiac Safety and eClinical Insights Solutions, ERT. “Our mobile, integrated ECG / eCOA tablet solution provides a single point of collection to optimize digital data quality and reduce burden for both clinical sites and sponsors.”
ERT continuously innovates to optimize the clinical research process in order to bring drug therapies to market faster and at a reduced cost. The global company is committed to expanding its current offering of integrated medical devices and wearables such as spirometers, glucose meters, blood pressure monitors, activity patches/meters and other devices to collect endpoints of import. ERT is bringing data collection to the patient by integrating individual Internet of Things (IoT) with electronic clinical outcome assessments, thereby increasing patient data values. By reimagining data management to deliver critical missing insights on clinical research for biopharmaceutical companies and CROs of every size at every stage in the drug development process, ERT innovates better health every day.
More information on the wireless ECG / eCOA integration and the Insights Cloud will be reviewed during a complimentary webinar on June 11, 2015. Register at http://www.ert.com/upcoming-webinars to participate in “Reducing Site Burden and Automating Real-Time Data Delivery: eCOA, ECG & EDC Integration.”
ERT will also demonstrate the new solution and many others at the ERT Innovation Lab Booth #2000 and also at the expanded ERT Booth #2025 during the Drug Information Association (DIA) Annual Meeting in Washington, DC beginning June 15, 2015. Additional information is available at http://www.ert.com/ecg-ecoa-tablet.
About ERT
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany.
Christine Tobin, ERT, http://www.ert.com/, +1 (412) 719-4568, [email protected]
Share this article